124 related articles for article (PubMed ID: 26927287)
21. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
22. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus.
Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H
Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
[TBL] [Abstract][Full Text] [Related]
24. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
25. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
26. [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].
Müller AK; Lenschow C; Palmes D; Senninger N; Hummel R; Lindner K
Chirurg; 2015 Sep; 86(9):874-80. PubMed ID: 25662991
[TBL] [Abstract][Full Text] [Related]
27. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
[TBL] [Abstract][Full Text] [Related]
28. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
30. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
32. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
[TBL] [Abstract][Full Text] [Related]
33. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
35. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
36. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
Vincent J; Mariette C; Pezet D; Huet E; Bonnetain F; Bouché O; Conroy T; Roullet B; Seitz JF; Herr JP; Di Fiore F; Jouve JL; Bedenne L;
Eur J Cancer; 2015 Sep; 51(13):1683-93. PubMed ID: 26163097
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
38. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
[TBL] [Abstract][Full Text] [Related]
39. The current status of neoadjuvant therapy for esophageal cancer.
Lin D; Leichman L
Semin Thorac Cardiovasc Surg; 2014; 26(2):102-9. PubMed ID: 25441001
[TBL] [Abstract][Full Text] [Related]
40. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
